In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

A new trial has found that a weight loss drug taken monthly helps people to lose 20 percent of their body weight. Other weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

Trial finds weight loss drug taken monthly helps people lose 20% of body weight - The new drug may rival other weight loss ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...